PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16407418-9	2006	CONCLUSION: XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine.	Cisplatin	112-121	X-ray repair cross complementing 3	Homo sapiens	12-17	
16407418-9	2006	CONCLUSION: XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine.	gemcitabine	122-133	X-ray repair cross complementing 3	Homo sapiens	12-17